Design, synthesis, and biological evaluation of acyl sulfonamide derivatives with spiro cycles as NaV1.7 inhibitors for antinociception

Bioorg Med Chem. 2023 May 15:86:117290. doi: 10.1016/j.bmc.2023.117290. Epub 2023 Apr 20.

Abstract

Chronic pain, as an unmet medical need, severely impacts the quality of life. The voltage-gated sodium channel NaV1.7 preferentially expressed in sensory neurons of dorsal root ganglia (DRG) serves a promising target for pain therapy. Here, we report the design, synthesis, and evaluation of a series of acyl sulfonamide derivatives targeting Nav1.7 for their antinociceptive activities. Among the derivatives tested, the compound 36c was identified as a selective and potent NaV1.7 inhibitor in vitro and exhibited antinociceptive effects in vivo. The identification of 36c not only provides a new insight into the discovery of selective NaV1.7 inhibitors, but also may hold premise for pain therapy.

Keywords: Pain; Spirocycles; Voltage-gated sodium channel subtype Na(V)1.7.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / pharmacology
  • Analgesics / therapeutic use
  • Animals
  • NAV1.7 Voltage-Gated Sodium Channel*
  • Pain / drug therapy
  • Quality of Life
  • Rats
  • Rats, Sprague-Dawley
  • Sodium Channel Blockers* / pharmacology
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use

Substances

  • Sodium Channel Blockers
  • NAV1.7 Voltage-Gated Sodium Channel
  • Sulfonamides
  • Analgesics